Current partner codePEPTIDESDE
NCT00259532·Not applicable·INTERVENTIONAL

Three New Methods for Diagnosing Pancreas Cancer

Status

Unknown

Phase

Not applicable

Enrollment

80

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.

Interventions

Treatment arms and agents.

PROCEDURE

Ultrasound and contrast agent

contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas

Timeline

From registration to results.

  1. First posted

    Nov 29, 2005

  2. Study start

    Feb 2005

  3. Primary completion

    Not reported

  4. Study completion

    Jan 2009

  5. Results posted

    Not reported

  6. Registry updated

    Feb 26, 2009

Outcomes

What the study measures.

Primary outcomes

Not reported in the indexed record.

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
Not reported
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * suspicion of cancer of the pancreas

Study locations

1 registered sites.

Denmark. Showing up to 24 locations stored in the fast local snapshot.

Copenhagen University Hospital

Copenhagen, Denmark

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Secretin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.